Frederick Raal to Humans
This is a "connection" page, showing publications Frederick Raal has written about Humans.
Connection Strength
5,788
-
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
Score: 0,074
-
Homozygous Familial Hypercholesterolemia Treatment: New Developments. Curr Atheroscler Rep. 2025 Jan 03; 27(1):22.
Score: 0,073
-
Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
Score: 0,073
-
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
Score: 0,071
-
Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease. S Afr Med J. 2024 May 09; 114(5):e1973.
Score: 0,070
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
Score: 0,069
-
Management of hyperlipidaemia. S Afr Med J. 2024 Mar 18; 114(3):e1016.
Score: 0,069
-
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
Score: 0,069
-
Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment. Ann Med. 2023 12; 55(1):2199218.
Score: 0,068
-
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023 11 30; 30(17):1874-1880.
Score: 0,068
-
Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor. S Afr Med J. 2023 Nov 06; 113(11):35-40.
Score: 0,068
-
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024 01 30; 149(5):354-362.
Score: 0,067
-
Regression of cutaneous xanthomata in patient with homozygous familial hypercholesterolemia using novel therapies. Lancet. 2023 09 02; 402(10404):e11.
Score: 0,067
-
Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023 07 11; 82(2):171-181.
Score: 0,066
-
Premature cardiovascular deaths. S Afr Med J. 2023 06 21; 113(7):6-7.
Score: 0,066
-
Lipid metabolism. Curr Opin Lipidol. 2023 06 01; 34(3):93-95.
Score: 0,066
-
Severe Hypophosphatemia: The Hidden Truth. Clin Chem. 2023 04 28; 69(5):450-453.
Score: 0,065
-
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
Score: 0,064
-
Statin Needs to be Continued During Paxlovid Therapy in COVID-19. Clin Infect Dis. 2022 12 19; 75(12):2281-2282.
Score: 0,064
-
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. Curr Atheroscler Rep. 2022 12; 24(12):959-967.
Score: 0,063
-
Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials. S Afr Med J. 2022 05 31; 112(6):426-432.
Score: 0,061
-
RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 2022 Apr 23; 21(1):41.
Score: 0,061
-
Statins: are they appropriate for all patients? Lancet Glob Health. 2022 03; 10(3):e305-e306.
Score: 0,060
-
Management of familial hypercholesterolemia in pregnancy. Curr Opin Lipidol. 2021 12 01; 32(6):370-377.
Score: 0,059
-
Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021 Nov-Dec; 15(6):814-821.
Score: 0,059
-
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol. 2021 08 01; 32(4):213-218.
Score: 0,058
-
Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female. Clin Chim Acta. 2021 Sep; 520:71-75.
Score: 0,057
-
Hyperpigmentation from Addison's Disease. N Engl J Med. 2021 May 06; 384(18):1752.
Score: 0,057
-
Novel therapies for familial hypercholesterolemia. Curr Opin Endocrinol Diabetes Obes. 2021 04 01; 28(2):188-195.
Score: 0,056
-
Evinacumab for Homozygous Familial Hypercholesterolemia. Reply. N Engl J Med. 2021 02 11; 384(6):e17.
Score: 0,056
-
Never too old to benefit from lipid-lowering treatment. Lancet. 2020 11 21; 396(10263):1608-1609.
Score: 0,055
-
New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. S Afr Med J. 2020 Oct 28; 110(11):13126.
Score: 0,055
-
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
Score: 0,054
-
The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Cardiovasc J Afr. 2020 Sep/Oct; 31(5):245-251.
Score: 0,054
-
Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
Score: 0,054
-
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020 06 02; 141(22):1829-1831.
Score: 0,053
-
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 04 16; 382(16):1520-1530.
Score: 0,053
-
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 02 18; 75(6):565-574.
Score: 0,052
-
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. Endocr Metab Immune Disord Drug Targets. 2020; 20(6):840-854.
Score: 0,052
-
A pain in the neck. BMJ. 2019 Nov 21; 367:l6008.
Score: 0,051
-
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 10 29; 74(17):2132-2146.
Score: 0,051
-
Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovasc J Afr. 2019 Sep/Oct 23; 30(5):279-284.
Score: 0,051
-
More aggressive lipid lowering in people with diabetes? Lancet Diabetes Endocrinol. 2019 08; 7(8):587-589.
Score: 0,050
-
Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. J Clin Lipidol. 2019 Sep - Oct; 13(5):735-743.
Score: 0,050
-
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
Score: 0,049
-
Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018 10; 277:483-492.
Score: 0,047
-
Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis. 2018 10; 277:502-507.
Score: 0,047
-
Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018 04 07; 39(14):1162-1168.
Score: 0,046
-
Population specific genetic heterogeneity of familial hypercholesterolemia in South Africa. Curr Opin Lipidol. 2018 04; 29(2):72-79.
Score: 0,046
-
Fibroblast growth factor-23 in patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2018 May - Jun; 12(3):767-772.
Score: 0,045
-
Treatment Gaps Found in the Management of Type 2 Diabetes at a Community Health Centre in Johannesburg, South Africa. J Diabetes Res. 2017; 2017:9536025.
Score: 0,044
-
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
Score: 0,043
-
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
Score: 0,042
-
Effect of Alirocumab on Lipoprotein(a) Over =1.5 Years (from the Phase 3 ODYSSEY Program). Am J Cardiol. 2017 Jan 01; 119(1):40-46.
Score: 0,041
-
The Effects of Mipomersen on Inhibiting Hepatic VLDL Apolipoprotein B100 Synthesis and Propensity for Hepatic Steatosis. Clin Chem. 2016 08; 62(8):1052-3.
Score: 0,040
-
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016 06; 57(6):1086-96.
Score: 0,040
-
Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J Clin Lipidol. 2016 Jul-Aug; 10(4):860-869.
Score: 0,040
-
Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
Score: 0,040
-
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016 05; 4(5):403-10.
Score: 0,040
-
Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease. Cardiovasc Drugs Ther. 2016 Feb; 30(1):101-8.
Score: 0,039
-
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Curr Cardiol Rep. 2015 Nov; 17(11):104.
Score: 0,039
-
Glycaemic, blood pressure and cholesterol control in 25 629 diabetics. Cardiovasc J Afr. 2015 Jul-Aug; 26(4):188-92.
Score: 0,038
-
Anacetrapib in familial hypercholesterolaemia: pros and cons. Lancet. 2015 May 30; 385(9983):2124-6.
Score: 0,037
-
New therapies for reducing low-density lipoprotein cholesterol. Endocrinol Metab Clin North Am. 2014 Dec; 43(4):1007-33.
Score: 0,036
-
The cardioprotective diet: carbohydrates versus fat. Cardiovasc J Afr. 2014 Nov-Dec; 25(6):302.
Score: 0,036
-
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
Score: 0,036
-
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
Score: 0,036
-
What matters most in pediatric familial hypercholesterolemia, genotype or phenotype? J Lipid Res. 2014 May; 55(5):793-5.
Score: 0,035
-
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.
Score: 0,034
-
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med. 2014; 65:417-31.
Score: 0,034
-
Targeting LDL: is lower better and is it safe? Best Pract Res Clin Endocrinol Metab. 2014 Jun; 28(3):309-24.
Score: 0,034
-
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
Score: 0,033
-
Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS). Cardiovasc J Afr. 2013 Sep; 24(8):330-8.
Score: 0,033
-
Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. Circulation. 2013 Jun 18; 127(24):2372-4.
Score: 0,033
-
Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013 Apr 24; 2(2):e000028.
Score: 0,033
-
Polygenic familial hypercholesterolaemia: does it matter? Lancet. 2013 Apr 13; 381(9874):1255-7.
Score: 0,032
-
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.
Score: 0,032
-
Lomitapide for homozygous familial hypercholesterolaemia. Lancet. 2013 Jan 05; 381(9860):7-8.
Score: 0,032
-
High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab Syndr Relat Disord. 2012 Oct; 10(5):351-7.
Score: 0,031
-
The cardiovascular health of the nation - should we be advocating a low-carbohydrate, high-fat diet? S Afr Med J. 2012 Jun 20; 102(9):740.
Score: 0,031
-
Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
Score: 0,030
-
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011 Nov 15; 124(20):2202-7.
Score: 0,029
-
A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
Score: 0,029
-
CEPHEUS SA: a South African survey on the undertreatment of hypercholesterolaemia. Cardiovasc J Afr. 2011 Sep-Oct; 22(5):234-40.
Score: 0,029
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
Score: 0,026
-
Carotid intima-media thickness is a predictor of coronary artery disease in South African black patients. Cardiovasc J Afr. 2009 Jul-Aug; 20(4):237-9.
Score: 0,025
-
Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord. 2009 Apr; 7(2):83-8.
Score: 0,025
-
Shift work and its effects on the cardiovascular system. Cardiovasc J Afr. 2008 Jul-Aug; 19(4):210-5.
Score: 0,023
-
Questioning the importance of LDL cholesterol: don't throw the baby out with the bathwater! Cardiovasc J Afr. 2008 Mar-Apr; 19(2):63-4.
Score: 0,023
-
A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct; 18(5):325-9.
Score: 0,022
-
Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry. Eur Heart J. 2025 Mar 24; 46(12):1127-1140.
Score: 0,019
-
Obesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study. PLoS One. 2025; 20(1):e0316527.
Score: 0,018
-
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2024 Dec 14; 404(10470):2462-2475.
Score: 0,018
-
Statins for the prevention of cardiovascular events associated with avian influenza: the COVID-19 pandemic as a reference. Ann Med. 2024 Dec; 56(1):2390166.
Score: 0,018
-
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
Score: 0,018
-
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
Score: 0,018
-
A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J S Afr. 2004 May-Jun; 15(3):118-23.
Score: 0,017
-
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia. JAMA Cardiol. 2024 Apr 01; 9(4):313-322.
Score: 0,017
-
The South African Lipid Guidelines: is there a need for an update? Cardiovasc J S Afr. 2004 Mar-Apr; 15(2):53-4.
Score: 0,017
-
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 Apr; 391:117472.
Score: 0,017
-
Does Engagement in HIV Care Affect Screening, Diagnosis, and Control of Noncommunicable Diseases in Sub-Saharan Africa? A Systematic Review and Meta-analysis. AIDS Behav. 2024 Feb; 28(2):591-608.
Score: 0,017
-
Gaps in the type 2 diabetes care cascade: a national perspective using South Africa's National Health Laboratory Service (NHLS) database. BMC Health Serv Res. 2023 Dec 21; 23(1):1452.
Score: 0,017
-
Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
Score: 0,017
-
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis. 2003 Dec; 171(2):273-9.
Score: 0,017
-
Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
Score: 0,017
-
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023 Jul 01; 44(25):2277-2291.
Score: 0,016
-
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023 12; 20(12):845-869.
Score: 0,016
-
Identifying the prevalence and correlates of multimorbidity in middle-aged men and women: a cross-sectional population-based study in four African countries. BMJ Open. 2023 03 14; 13(3):e067788.
Score: 0,016
-
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19. Curr Opin Lipidol. 2023 06 01; 34(3):119-125.
Score: 0,016
-
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 01 07; 44(2):129-138.
Score: 0,016
-
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 12 21; 43(48):5047-5057.
Score: 0,016
-
Non-HDL-C and LDL-C/HDL-C are associated with self-reported cardiovascular disease in a rural West African population: Analysis of an array of lipid metrics in an AWI-Gen sub-study. PLoS One. 2022; 17(12):e0278375.
Score: 0,016
-
Drug-drug interaction with oral antivirals for the early treatment of COVID-19. Int J Infect Dis. 2023 02; 127:171-172.
Score: 0,016
-
Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation. Lipids Health Dis. 2022 Nov 01; 21(1):113.
Score: 0,016
-
Familial Hypercholesterolemia Identification by Machine Learning Using Lipid Profile Data Performs as Well as Clinical Diagnostic Criteria. Circ Genom Precis Med. 2022 10; 15(5):e003324.
Score: 0,016
-
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.
Score: 0,016
-
Monkeypox is a global public health emergency: The role of repurposing cholesterol lowering drugs not to be forgotten. J Clin Lipidol. 2022 Sep-Oct; 16(5):757-758.
Score: 0,016
-
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):676-684.
Score: 0,015
-
Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.
Score: 0,015
-
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022 02 19; 399(10326):719-728.
Score: 0,015
-
Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3. Future Cardiol. 2022 02; 18(2):143-153.
Score: 0,015
-
Familial hypercholesterolaemia in South Africa: A reminder. S Afr Med J. 2021 08 02; 111(8):700-701.
Score: 0,014
-
From lipodystrophy syndromes to diabetes mellitus. Lancet. 2001 May 05; 357(9266):1379-81.
Score: 0,014
-
A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021 05; 325:46-56.
Score: 0,014
-
Cerebrotendinous xanthomatosis without neurological involvement. J Intern Med. 2021 11; 290(5):1039-1047.
Score: 0,014
-
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 03 09; 77(9):1182-1193.
Score: 0,014
-
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. J Clin Lipidol. 2021 Mar-Apr; 15(2):379-380.
Score: 0,014
-
Poor cardiovascular health is associated with subclinical atherosclerosis in apparently healthy sub-Saharan African populations: an H3Africa AWI-Gen study. BMC Med. 2021 02 10; 19(1):30.
Score: 0,014
-
Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. Atherosclerosis. 2021 03; 320:53-60.
Score: 0,014
-
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020 06 21; 41(24):2313-2330.
Score: 0,013
-
Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Jun; 150(2):421-8.
Score: 0,013
-
Cryptogenic Cushing Syndrome Due to a White Lie. Clin Chem. 2020 05 01; 66(5):658-663.
Score: 0,013
-
A patient requiring 1,000 units of insulin per day! S Afr Med J. 2000 Apr; 90(4):357-8.
Score: 0,013
-
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 04 16; 382(16):1507-1519.
Score: 0,013
-
Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. PLoS One. 2020; 15(2):e0229098.
Score: 0,013
-
Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020 06; 17(6):360-377.
Score: 0,013
-
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999 Dec 01; 84(11):1344-6, A7.
Score: 0,013
-
Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. Curr Atheroscler Rep. 2019 11 19; 21(12):48.
Score: 0,013
-
Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
Score: 0,013
-
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020 01; 8(1):50-67.
Score: 0,013
-
Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa. Cardiovasc J Afr. 2019 Sep/Oct; 30(5):297-304.
Score: 0,013
-
Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. J Intern Med. 1999 Jul; 246(1):75-80.
Score: 0,013
-
Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol. 1999 May 01; 83(9):1330-3.
Score: 0,012
-
Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 03 15; 19(1):61.
Score: 0,012
-
Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr. 2019 Jan/Feb 23; 30(1):15-23.
Score: 0,012
-
South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018 10 26; 108(11b):973-1000.
Score: 0,012
-
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct; 41(10):1328-1335.
Score: 0,012
-
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018 10; 277:234-255.
Score: 0,012
-
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018 07 14; 39(27):2526-2539.
Score: 0,012
-
Familial hypercholesterolemia: potential diagnostic value of mutation screening in a pediatric population of South Africa. Clin Genet. 1998 Jul; 54(1):74-8.
Score: 0,012
-
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. J Clin Lipidol. 2018 Sep - Oct; 12(5):1199-1207.
Score: 0,012
-
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
Score: 0,011
-
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997 Dec; 135(2):249-56.
Score: 0,011
-
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Nov - Dec; 11(6):1448-1457.
Score: 0,011
-
The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
Score: 0,011
-
Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. J Am Coll Cardiol. 2017 Aug 29; 70(9):1162-1170.
Score: 0,011
-
A double mutant LDL receptor allele in a cypriot family with heterozygous familial hypercholesterolemia. Hum Genet. 1997 Jul; 100(1):101-3.
Score: 0,011
-
CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet. 1997 Jun; 51(6):394-8.
Score: 0,011
-
Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects. Atherosclerosis. 1997 Feb 28; 129(1):97-102.
Score: 0,011
-
Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease. Clin Chim Acta. 1997 Feb 03; 258(1):31-46.
Score: 0,011
-
Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl. 2016 Dec; 22:1-32.
Score: 0,010
-
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016 Oct; 30(5):473-483.
Score: 0,010
-
Comprehensive management of non-insulin-dependent diabetes mellitus. A diabetes clinic revisited. S Afr Med J. 1996 Aug; 86(8 Suppl):1007-8, 1013.
Score: 0,010
-
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016 10; 4(10):850-61.
Score: 0,010
-
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
Score: 0,010
-
Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016 May 02; 23(5):567-87.
Score: 0,010
-
The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015 Dec 01; 132(22):2167-92.
Score: 0,010
-
Familial hypercholesterolaemia: A global call to arms. Atherosclerosis. 2015 Nov; 243(1):257-9.
Score: 0,010
-
Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2015 Nov; 35(11):2269-80.
Score: 0,010
-
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21; 36(36):2425-37.
Score: 0,009
-
Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. Atherosclerosis. 1995 May; 115(1):9-15.
Score: 0,009
-
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1489-99.
Score: 0,009
-
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.
Score: 0,009
-
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. Turk Kardiyol Dern Ars. 2015 Mar; 43 Suppl 1:1-14.
Score: 0,009
-
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015 May 01; 36(17):1012-22.
Score: 0,009
-
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
Score: 0,009
-
Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015 Mar-Apr; 9(2):201-9.
Score: 0,009
-
Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr. 1994 Oct; 60(4):579-85.
Score: 0,009
-
Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS One. 2014; 9(8):e102830.
Score: 0,009
-
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014 Aug 21; 35(32):2146-57.
Score: 0,009
-
Lower levels of high-density lipoprotein cholesterol in urban Africans presenting with communicable versus non-communicable forms of heart disease: the 'Heart of Soweto' hospital registry study. BMJ Open. 2014 Jul 14; 4(7):e005069.
Score: 0,009
-
Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. Atherosclerosis. 1994 Jun; 107(2):213-9.
Score: 0,009
-
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015 Jul; 22(7):849-54.
Score: 0,009
-
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
Score: 0,009
-
Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014 Mar-Apr; 8(2):148-72.
Score: 0,009
-
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug; 2(8):655-66.
Score: 0,009
-
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014 Feb 15; 171(3):309-25.
Score: 0,008
-
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14; 129(2):234-43.
Score: 0,008
-
A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014 Jan; 15(1):3-12.
Score: 0,008
-
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
Score: 0,008
-
The age of onset and sex distribution of insulin-dependent diabetes mellitus in Africans in South Africa. Postgrad Med J. 1993 Jul; 69(813):552-6.
Score: 0,008
-
The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
Score: 0,008
-
Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease. Cardiovasc J Afr. 2012 Aug; 23(7):389-95.
Score: 0,008
-
The relationship between the development and progression of microalbuminuria and arterial blood pressure in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract. 1992 Jun; 16(3):221-7.
Score: 0,008
-
Fat, protein and carbohydrate content of diets of white insulin-dependent diabetic adolescents and young adults. S Afr Med J. 1992 Apr 18; 81(8):399-402.
Score: 0,008
-
Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Hemodial Int. 2012 Jan; 16(1):59-68.
Score: 0,007
-
Meeting of the minds. Should pre-hypertension in type 2 diabetes be treated? Cardiovasc J Afr. 2010 May-Jun; 21(3 Suppl):S9-S13.
Score: 0,007
-
Comparison between surrogate indices of insulin sensitivity and resistance, and the hyperinsulinaemic euglycaemic glucose clamp in urban South African blacks with and without coronary artery disease. Diab Vasc Dis Res. 2010 Apr; 7(2):151-7.
Score: 0,007
-
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010 Feb; 156(2):231-6.e1-3.
Score: 0,006
-
Leptin, adiponectin, and high-sensitivity C-reactive protein in relation to the metabolic syndrome in urban South African blacks with and without coronary artery disease. Metab Syndr Relat Disord. 2009 Jun; 7(3):243-8.
Score: 0,006
-
Postprandial hyperglycemia in urban South African blacks with and without coronary artery disease. Metab Syndr Relat Disord. 2009 Feb; 7(1):23-9.
Score: 0,006
-
Haematological abnormalities in the acquired immunodeficiency syndrome. S Afr Med J. 1988 Aug 20; 74(4):157-60.
Score: 0,006
-
Discovering familial hypercholesterolaemia. S Afr Med J. 2008 Apr; 98(4):232.
Score: 0,006
-
The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr. 2008 Mar-Apr; 19(2):88-94.
Score: 0,006
-
Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. QJM. 2008 Feb; 101(2):111-9.
Score: 0,006
-
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar; 197(1):400-6.
Score: 0,006
-
Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clin Chim Acta. 2007 Mar; 378(1-2):33-7.
Score: 0,005
-
Metabolic syndrome, undiagnosed diabetes mellitus and insulin resistance are highly prevalent in urbanised South African blacks with coronary artery disease. Cardiovasc J S Afr. 2006 Mar-Apr; 17(2):50-5.
Score: 0,005
-
Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids. Cardiovasc J S Afr. 2005 Mar-Apr; 16(2):112-7.
Score: 0,005
-
High-dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc J S Afr. 2004 Mar-Apr; 15(2):70-5.
Score: 0,004
-
Basal endocrine status in African dietary iron overload. Endocrine. 2003 Aug; 21(3):241-4.
Score: 0,004
-
Phytosterols--a new dietary aid for the treatment of hypercholesterolaemia. S Afr Med J. 2003 Aug; 93(8):581-2.
Score: 0,004
-
Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. Transplantation. 2002 Feb 27; 73(4):587-90.
Score: 0,004
-
Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolemia--which is more important? Clin Chim Acta. 2001 Dec; 314(1-2):167-73.
Score: 0,004
-
Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001 Aug; 28(4):365-70.
Score: 0,004
-
Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. Am J Hum Genet. 2001 May; 68(5):1172-88.
Score: 0,004
-
Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia? Clin Chim Acta. 2000 Mar; 293(1-2):105-13.
Score: 0,003
-
Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem. 2000 Mar; 37 ( Pt 2):174-8.
Score: 0,003
-
Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000 Feb; 20(2):522-8.
Score: 0,003
-
Circulating endothelium-related adhesion molecules in black South African patients with Graves' disease. Endocrine. 2000 Feb; 12(1):21-3.
Score: 0,003
-
Mutation analysis in familial hypercholesterolemia patients of different ancestries: identification of three novel LDLR gene mutations. Mol Cell Probes. 1998 Jun; 12(3):149-52.
Score: 0,003
-
Two novel and two known low-density lipoprotein receptor gene mutations in German patients with familial hypercholesterolemia. Hum Mutat. 1998; Suppl 1:S232-3.
Score: 0,003
-
Insulin receptor substrate-1 gene variants in lipoatrophic diabetes mellitus and non-insulin-dependent diabetes mellitus: a study of South African black and white subjects. Hum Genet. 1997 Nov; 101(1):118-9.
Score: 0,003
-
Improved glucose tolerance after effective lipid-lowering therapy with bezafibrate in a patient with lipoatrophic diabetes mellitus: a putative role for Randle's cycle in its pathogenesis? Clin Endocrinol (Oxf). 1997 Mar; 46(3):365-8.
Score: 0,003
-
Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy. Osteoporos Int. 1997; 7(4):376-89.
Score: 0,003
-
Screening for diabetic retinopathy in South Africa with 60 degrees retinal colour photography. J Intern Med. 1996 Jan; 239(1):43-7.
Score: 0,002
-
Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 1995 Mar; 113(2):289-92.
Score: 0,002
-
Insulin resistance or insulin deficiency as precursor of non-insulin-dependent diabetes mellitus. Lancet. 1994 Dec 17; 344(8938):1705.
Score: 0,002
-
Selected risk factors for coronary heart disease in male scholars from the major South African population groups. S Afr Med J. 1993 Dec; 83(12):891-7.
Score: 0,002
-
Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb. 1993 Jul; 13(7):1076-81.
Score: 0,002
-
Pathogenesis of non-insulin-dependent diabetes mellitus in the black population of southern Africa. Lancet. 1992 Aug 22; 340(8817):460-2.
Score: 0,002
-
Relationship between plasma insulin and blood pressure in South African black women in Johannesburg. Diabetes Care. 1992 Apr; 15(4):556-8.
Score: 0,002
-
Insulin-receptor activity in nondiabetic and diabetic urbanized South African black women. Diabetes Care. 1992 Feb; 15(2):277-81.
Score: 0,002
-
Cerebral phaeohyphomycosis caused by Xylohypha bantiana. Eur J Clin Microbiol Infect Dis. 1989 Nov; 8(11):984-8.
Score: 0,002